Next Gen Diagnostics and Standard BioTools Partner to Revolutionize Pathogen Sequencing Automation
SOUTH SAN FRANCISCO, Calif. Feb. 26, 2024 - Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose - Unleashing tools to accelerate breakthroughs in human health - and Next Gen Diagnostics have announced a groundbreaking partnership. This long-term agreement aims to revolutionize the automation of sample preparation for pathogen whole genome sequencing, bringing forth a new era of advanced diagnostics.
Under this exclusive agreement, Standard BioTools will take the lead in manufacturing the NGD-100, a tailored version of its proprietary microfluidics-based Biomark X9 System, customized specifically for Next Gen Diagnostics (NGD). The NGD-100 system will be optimized for automated pathogen WGS (whole genome sequencing) library preparation, thereby enhancing the efficiency, accuracy, and affordability of pathogen identification and characterization.
Pathogen whole genome sequencing plays a vital role in identifying and understanding infectious diseases. By analyzing the entire DNA sequence of a pathogen, scientists can uncover critical insights into its composition, virulence, and potential response to various treatments. However, the complex and time-consuming nature of sample preparation has been a major bottleneck in the adoption of this powerful diagnostic tool.
This partnership between Standard BioTools and Next Gen Diagnostics aims to address this challenge head-on. By harnessing the cutting-edge technology of Standard BioTools’ microfluidics-based Biomark X9 System, the NGD-100 will offer a high-throughput and efficient solution for automated pathogen WGS library preparation. This will not only streamline the workflow but also significantly reduce the cost and time required for sequencing analysis.
The NGD-100 system will pave the way for more widespread adoption of pathogen sequencing in clinical labs, research institutions, and public health agencies. With automated sample preparation, researchers can focus their efforts on analyzing the data and deriving valuable insights, ultimately leading to quicker and more accurate diagnoses, improved outbreak surveillance, and better-informed treatment strategies.
Dr. Jane Stevens, CEO of Standard BioTools, expressed her excitement about the partnership, stating, We believe that by combining our expertise in microfluidics and automation with Next Gen Diagnostics’ vision for advancing the field of pathogen sequencing, we can truly transform the way infectious diseases are diagnosed and managed.
Erik Johnson, CEO of Next Gen Diagnostics, echoed these sentiments, saying, The NGD-100 system represents a significant leap forward in automated sample preparation, making pathogen sequencing accessible to a wider range of institutions. This collaboration between Next Gen Diagnostics and Standard BioTools has the potential to greatly improve public health outcomes.
With this collaborative effort, the future of pathogen whole genome sequencing looks brighter than ever. As Standard BioTools and Next Gen Diagnostics join forces, their dedication to accelerating breakthroughs in human health is set to revolutionize the field of pathogen diagnostics and improve global disease management.
Comments